Zareian Bita, Ghadbeighi Sajad, Amirhamzeh Amirali, Ostad Seyed N, Shafiee Abbas, Amini Mohsen
Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Med Chem. 2016;12(4):394-401. doi: 10.2174/1573406412666151112125149.
Triaryl oxadiazoles have been proven to be useful agents against various types of cancer cell lines. Nevertheless, their mechanism of action is not fully understood.
Synthesis and cytotoxic activity of a new group of triaryl oxadiazoles; 3,4-diaryl-5-(4- pyridinyl)-1,2,4-oxadiazole derivatives, will be discussed in this study. Their cytotoxic activity has been examined in 4 different cell lines by MTT method.
3,4-Diaryl-5-(4-pyridinyl)-1,2,4-oxadiazole derivatives were prepared from condensation of different imines with 4-substituted benzohydroxyiminoyl chlorides. The antiproliferative activity of the final compounds was examined in MCF-7, AGS, HT-29 and NIH3T3 cell lines by MTT assay, using different concentrations of each compound to determine their IC50. The cytotoxic activity of paclitaxel, doxorubicin and combretastatin A-4 was evaluated as positive controls.
All compounds demonstrated cytotoxic activity in mentioned cell lines, in a dose dependent manner. Among all, 6d-2 showed the highest cytotoxicity in AGS and MCF-7 cell lines with IC50 19.84 and 9.91 respectively and 6c-2 was the most potent in HT-29 with IC50 27.60. In addition, 6c-1, one of the most potent compounds, showed an interestingly low cytotoxic effect on NIH3T3 cell line, which is a noncancerous cell line. In the molecular modeling study, all compounds had comparable binding energy in Colchicine binding site and 6c-2 had the best-predicted binding energy.
Together, our data suggest that the synthesized compounds have a partially selective mechanism of action against cancer cells and possibly a lower toxic effect on normal cells, making them interesting candidates for the synthesis of new anticancer agents.
三芳基恶二唑已被证明是对抗各种癌细胞系的有效药物。然而,它们的作用机制尚未完全明确。
本研究将探讨一组新型三芳基恶二唑;3,4 - 二芳基 - 5 -(4 - 吡啶基)- 1,2,4 - 恶二唑衍生物的合成及细胞毒性活性。已通过MTT法在4种不同细胞系中检测了它们的细胞毒性活性。
由不同的亚胺与4 - 取代苯甲酰羟基亚胺酰氯缩合制备3,4 - 二芳基 - 5 -(4 - 吡啶基)- 1,2,4 - 恶二唑衍生物。通过MTT法在MCF - 7、AGS、HT - 29和NIH3T3细胞系中检测最终化合物的抗增殖活性,使用每种化合物的不同浓度来确定其IC50。以紫杉醇、多柔比星和康普瑞他汀A - 4的细胞毒性活性作为阳性对照。
所有化合物在上述细胞系中均表现出剂量依赖性的细胞毒性活性。其中,6d - 2在AGS和MCF - 7细胞系中表现出最高的细胞毒性,IC50分别为19.84和9.91,6c - 2在HT - 29细胞系中最有效,IC50为27.60。此外,最有效的化合物之一6c - 1对非癌细胞系NIH3T3细胞系表现出极低的细胞毒性作用。在分子模拟研究中,所有化合物在秋水仙碱结合位点具有相当的结合能,6c - 2具有最佳预测结合能。
总之,我们的数据表明合成的化合物对癌细胞具有部分选择性作用机制,并且对正常细胞可能具有较低的毒性作用,使其成为合成新型抗癌药物的有趣候选物。